Fol­low­ing clin­i­cal hold lift, Astel­las posts ear­ly Pompe gene ther­a­py da­ta

Fresh out of a clin­i­cal hold, Astel­las is spot­light­ing da­ta on its gene ther­a­py for Pompe dis­ease.

In four pa­tients who got an in­fu­sion of the gene ther­a­py, called AT845, three dis­con­tin­ued en­zyme re­place­ment ther­a­py. As of the Sept. 15 cut­off, those three pa­tients have been off en­zyme re­place­ment ther­a­py for 19, 44 and 51 weeks, re­spec­tive­ly.

Astel­las did not bring any da­ta on the pri­ma­ry ef­fi­ca­cy end­point — en­zyme ex­pres­sion and ac­tiv­i­ty — though it did present sec­ondary ef­fi­ca­cy da­ta. The three par­tic­i­pants who were tak­en off ERT main­tained sim­i­lar re­sults in forced vi­tal ca­pac­i­ty, a mea­sure of lung ca­pac­i­ty, af­ter stop­ping bi­week­ly treat­ments. In ad­di­tion, two of the three had con­sis­tent re­sults on a six-minute walk test af­ter be­ing tak­en off ERT. The third saw a de­crease in dis­tance walked on the test af­ter they de­vel­oped a case of pe­riph­er­al neu­ropa­thy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER